| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
AEON Biopharma, Inc.$0.48
-0.02 (-3.9%)
D 24Pipeline Score Richly Valued Pharma · Clinical
Market Cap
20.45 M
EPS
-4.35
P/E Ratio
-
Value Trade
7.03 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.03 M
Operating CF
-2.64 M
Total Assets
8.63 M
Total Liabilities
25.38 M
Equity
-16.75 M
D/E Ratio
12,345
-0.36 %
Week
-29.35 %
1 Month
-35.23 %
3 Month
-3.42 %
6 Month
-99.89 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
6.24 M
Monthly Burn
879.00 K
Runway
5.4 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
66.19 K
52 Week Range
0.53 - 1.45
% held by Insiders
74.5 %
% held by Institutions
10.8 %
Enterprise Value
16.83 M
Total Shares
26.28 M
Short %
1.7 %
Float Shares
9.43 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AEON Biopharma, Inc.
201Total events
5Upcoming
40Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
Aug 3, 2026
T2Quarterly Update
Deadline to regain compliance with NYSE American continued listing standards
Aug 3, 2026
T2Timing Guidance
Plan Period ends; AEON must regain compliance by August 3, 2026 or face potential delisting
Aug 3, 2026
T2Restructuring Layoffs
Deadline to regain compliance with NYSE American listing standards
Event history 196
Jun 4, 2026
▲Poster PresentationABP-450Presentation
Poster presentation of structural and functional comparability data for ABP-450 vs BOTOX at AHS 2026
chronic migrainesource ↗
Apr 22, 2026
◆Poster PresentationABP-450Presentation
Poster presentation at 2026 AAN Annual Meeting: Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA
Apr 18, 2026
◆Poster PresentationABP-450Presentation
Poster presentation at 2026 AAN Annual Meeting: Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA
Apr 2026
●Poster PresentationABP-450Presentation
Poster presentation at 2026 AAN Annual Meeting on primary structure comparability between ABP-450 and onabotulinumtoxinA
Q2 2026
◆Type B MeetingABP-450FDA Meeting
Planned BPD Type 2b meeting with FDA to discuss remaining biosimilar development plan
Mar 31, 2026
▼Quarterly UpdateCorporate
Received additional NYSE American notice for non-compliance with Section 1003(a)(ii)
Q1 2026
▲FDA Feedback ReceivedABP-450FDA Meeting
FDA BPD Type 2a meeting feedback supporting ABP-450 analytical similarity strategy under 351(k) pathway
Drug Pipeline Intelligence
D24
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 24%
Micro Cap (rank 693 of 911)
Percentile RankAEON Biopharma, Inc. faces pipeline headwinds (24/100), with $232M risk-adjusted pipeline value, led by ABP-450 in Migraine (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABP-450 Small molecule | Cervical Dystonia | Phase 2 | NCT04871451 | 11% | $161M | COMPLETED | 112 | - | - | Jul 24, 2023 | - | Aug 22, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ABP-450 | chronic migraine | — | 2026-06-04 | 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins; no variant peptides observed between ABP-450 and BOTOX®; all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference results Read More | AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society Read More | |
ABP-450 | chronic migraine | — | 2026-06-04 | 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins; no variant peptides observed between ABP-450 and BOTOX®; all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference results Read More | AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society Read More | |
ABP-450 | chronic migraine | — | 2026-06-04 | 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins; no variant peptides observed between ABP-450 and BOTOX®; all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference results Read More | AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AEON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AEON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AEONAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
AEON Biopharma presented new data at the AHS Annual Scientific Meeting, demonstrating the structural and functional comparability of ABP-450 to BOTOX®. The findings, which include genomic sequence alignment and potency assays, support the biosimilarity of ABP-450, enhancing its potential for U.S. market entry. This data is crucial for AEON's strategy in the therapeutic neurotoxin market.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data)
AEON Biopharma reported its first quarter 2026 financial results, highlighting progress on its ABP-450 biosimilar program, including favorable feedback from the FDA regarding its analytical similarity strategy. The company has significantly improved its financial standing by reducing outstanding debt by over 90% through recent financing initiatives. Furthermore, AEON announced the appointment of John Bencich as its new Chief Financial Officer. The company aims to request a Type 2b meeting with the FDA in 2026 to discuss the next steps in obtaining approval for ABP-450 as a biosimilar to BOTOX.
Read more →AEONDisrupting a $3.5B neurotoxin market dominated by a single brand for 30 years CORPORATE PRESENTATION / MAY 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A This presentation includes forward-looking state
AEON is actively pursuing the development of ABP-450, a biosimilar to BOTOX, aiming to disrupt the $3.5 billion neurotoxin market. With strong analytical data demonstrating high similarity to BOTOX and successful engagement with the FDA, AEON is on track for full-label approval. Recent financing efforts have bolstered the company’s cash flow and strategic initiatives, positioning it favorably against a long-standing market monopoly. The pathway to market includes navigating complex regulatory requirements and demonstrating equivalent efficacy and safety profiles to potential partners and clinicians.
Read more →AEONAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma reported its first quarter 2026 financial results, highlighting positive feedback from the FDA regarding its ABP-450 biosimilar development. The company significantly reduced its debt by over 90% through financing transactions. Additionally, AEON appointed John Bencich as Chief Financial Officer to strengthen its leadership team and is preparing for further FDA interactions to advance its product towards full-label approval.
Read more →AEONAEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma has scheduled its Annual Shareholder Meeting for June 17, 2026, at its office in Irvine, California. The company is progressing with ABP-450, a biosimilar to BOTOX®, aiming for full-label U.S. entry. However, an audit report has revealed a going concern qualification, highlighting liquidity challenges. Despite upcoming shareholder engagement, the company faces uncertainties over financing and adherence to exchange listing standards.
Read more →AEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma has announced the grant of inducement awards to newly appointed Chief Financial Officer John Bencich. The awards, consisting of restricted and performance-based stock units, are part of the company's 2025 Employment Inducement Incentive Award Plan. This move comes as AEON works towards gaining full-label access to the U.S. therapeutic neurotoxin market with its product ABP-450, a biosimilar to BOTOX. While the therapeutic market represents a significant opportunity, AEON must navigate challenges related to stock exchange compliance and other uncertainties.
Read more →AEONAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma, Inc. received a notice from NYSE American indicating non-compliance with continued listing standards following its financial results. The company's stockholders' deficit is approximately $55 million, leading to concerns regarding compliance with multiple sections of the NYSE Company Guide. AEON is executing a plan to regain compliance by August 3, 2026, but failure to meet this deadline may result in delisting. The company continues to trade under the symbol 'AEON' despite its current noncompliance status.
Read more →AEONcomplex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau . ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S
AEON Biopharma has received another notice from NYSE American indicating it is not in compliance with continued listing standards. The company reported significant financial losses, resulting in a $55 million stockholders' deficit. Despite having an approved plan to regain compliance by August 2026, failure to meet standards may result in delisting proceedings. The company's operations and obligations to the SEC remain unaffected by this notice.
Read more →AEON▼ -14.7%on this news
AEON BIOPHARMA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) Years Ended
AEON Biopharma, Inc. announced its financial results for the year ending December 31, 2025, highlighting positive initial results for its biosimilar ABP-450 in relation to BOTOX. The company received encouraging FDA feedback which supports its continued regulatory efforts for the ABP-450 program. AEON has also strengthened its financial position through PIPE financing, significantly reducing its debt. The development pathway remains contingent upon further analytical testing and regulatory engagement.
Read more →AEON▼ -14.7%on this news
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma has released its financial results for the year ended December 31, 2025, highlighting positive initial comparative analytical results for its ABP-450 biosimilar to BOTOX®. The company received favorable feedback from the FDA that outlines a clear framework for advancing its biosimilar development. Additionally, AEON has improved its financial standing through a $6 million PIPE financing and a debt reduction strategy, significantly decreasing its outstanding liabilities. Looking ahead, AEON plans a BPD Type 2b meeting with the FDA in 2026 to discuss the next phases of its development plan for ABP-450.
Read more →AEONAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma received positive feedback from the FDA following a BPD Type 2a meeting regarding its ABP-450 biosimilar program. The FDA supported AEON's analytical similarity strategy under the 351(k) pathway, acknowledging the challenges of characterizing the botulinum neurotoxin complex. AEON plans to request a BPD Type 2b meeting in 2026 to discuss further development steps.
Read more →AEONAEON Biopharma Appoints John Bencich as Chief Financial Officer
AEON Biopharma has appointed John Bencich as its new Chief Financial Officer, aiming to enhance the company's financial strategy as it approaches critical regulatory milestones. Bencich brings over 25 years of experience in corporate strategy and financial leadership from several biotechnology firms. His role will be integral in supporting the company's growth and execution strategies as they advance their lead biosimilar product, ABP-450, geared towards competing in the $3 billion U.S. therapeutic neurotoxin market. AEON is focused on positioning itself for long-term value creation during this pivotal phase of development.
Read more →AEON▼ -5.5%on this newsshared move
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
AEON Biopharma has announced that its abstract focused on ABP-450, a biosimilar to BOTOX, has been accepted for presentation at the 2026 American Academy of Neurology Annual Meeting. The presentation will detail analytical data confirming the primary amino acid sequence similarity between ABP-450 and the reference product. This acceptance reflects AEON's ongoing efforts to establish itself in the competitive biosimilars market and to build credibility among neurologists, who are responsible for a significant volume of therapeutic botulinum toxin treatments.
Read more →AEON▼ -14%on this news
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
AEON Biopharma has successfully completed its BPD Type 2a meeting with the FDA, marking a significant procedural milestone. The company is now awaiting the official meeting minutes, which are expected to guide the next steps for developing ABP-450, its biosimilar to BOTOX. Additionally, AEON shareholders have approved key proposals to finalize transactions announced in November, enhancing the company's financial stability.
Read more →AEON▲ +13.3%on this newsshared move
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions - AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior
AEON Biopharma reported the successful conclusion of its BPD Type 2a meeting with the FDA, which is a critical milestone for the company's development of ABP-450, its biosimilar to BOTOX. Additionally, AEON shareholders approved key transactions related to PIPE financing and a note exchange with Daewoong Pharmaceutical, which are expected to improve the company's capital structure. The company anticipates receiving official minutes from the FDA meeting in approximately 30 days, informing the next steps in the biosimilar's development.
Read more →AEONBringing Biosimilar Competition to a U.S. Therapeutic Neurotoxin Market Still Dominated by a Single Brand ABP-450 is being developed as a biosimilar to BOTOX®, aiming to become the first complete therapeutic alterna
AEON is developing ABP-450 as a biosimilar to BOTOX, seeking to enter the therapeutic neurotoxin market, which is currently dominated by a single brand. The company has secured $6 million in PIPE financing, enabling potential acceleration of its development program. Positive data supporting the biosimilarity of ABP-450 has strengthened its position ahead of an FDA meeting scheduled for January 2026, while shareholder approval for further financing measures will be crucial in the coming months. The development strategy includes a focus on similarity to FDA standards as a pathway to competitiveness.
Read more →AEON▲ +5.1%on this news· ran to +25% by day 1
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
AEON Biopharma has announced the execution of an exchange agreement with Daewoong Pharmaceutical to convert $15 million of notes and accrued interest into new equity and cash-exercise warrants for 8 million shares. The exchange, which requires shareholder approval, is expected to eliminate more than 90% of AEON's outstanding debt, thus strengthening the company’s financial position and aligning Daewoong's long-term strategic interests with AEON. The agreement is seen as a crucial step forward in AEON's plans for its ABP-450 biosimilar strategy.
Read more →AEON▲ +5.1%on this news· ran to +25% by day 1
relevant materials and any other documents filed by the Company with the SEC may be obtained free of charge at the SEC's website, at www.sec.gov. In addition, stockholders may obtain free copies of the proxy statement an
AEON Biopharma has announced a definitive agreement with Daewoong Pharmaceutical to exchange $15 million of convertible notes into new equity and additional financing instruments. This exchange, expected to eliminate over 90% of AEON's outstanding debt, is a significant step in strengthening the company's financial position and supporting the development of its biosimilar product, ABP-450. However, the implementation of the agreement is contingent on shareholder approval, posing an element of risk. The company's leadership remains optimistic about future progress despite potential uncertainties.
Read more →AEON▼ -8.2%on this news
Advancing a Proven Molecule Toward Full-Label Biosimilar Approval Fresh Data | New Capital | Simplified Structure – Positioned for Acceleration CORPORATE PRESENTATION / DECEMBER 2025 NYSEAMERICAN: AEON © 2 0
AEON is positioning its biosimilar ABP-450 for full-label approval, with momentum driven by recent financing and partnerships. The company completed its first PIPE financing round and is preparing for a second that depends on shareholder approval. ABP-450 aims to compete in the therapeutic toxin market, traditionally dominated by BOTOX, addressing high costs and promoting patient access through value-driven economics. While there are positive advancements in their strategy, risks related to financing terms and shareholder dependencies remain.
Read more →AEON▼ -12.8%on this news
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
AEON Biopharma announced the successful first closing of its private placement financing, which generated approximately $1.79 million. The company also provided an update regarding its FDA Type 2a meeting, which has been rescheduled for January 21, 2026. This meeting aims to review AEON's analytical development plan related to its BOTOX biosimilar, ABP-450. The financial proceeds are expected to support the company's ongoing analytical program and may expedite the development timeline of ABP-450.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30
AEON Biopharma, Inc. announced its financial results for the third quarter of 2025, highlighting positive biosimilarity data for its drug ABP-450, which shows an identical amino-acid sequence to BOTOX. The company plans to present this data at an upcoming FDA Type 2a meeting scheduled for November 19, 2025. Additionally, AEON has initiated two financing transactions aimed at significantly reducing its debt and extending its cash runway, which could also accelerate the ABP-450 biosimilar program by up to six months. Overall, these developments position AEON for potential growth in the U.S. therapeutic neurotoxin market.
Read more →AEONAEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
AEON Biopharma reported positive results from its third quarter 2025, highlighting favorable biosimilarity data for its product ABP-450, aimed at competing with BOTOX. The firm announced complementary financing transactions to significantly reduce its debt and extend its operational runway, which is expected to accelerate the ABP-450 program. As AEON prepares for an FDA Type 2a meeting, it emphasizes confidence in both their scientific results and financial position moving forward.
Read more →AEONAEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
AEON Biopharma announced two funding transactions totaling up to ~$22 million, aimed at strengthening its balance sheet and reducing outstanding debt significantly. The company plans to raise $6 million through a private placement, with potential for an additional $7 million through warrants. Additionally, AEON and Daewoong Pharmaceutical have agreed to exchange $15 million in convertible notes for equity, which would dramatically reduce AEON's debt. These funds will support AEON's ongoing ABP-450 biosimilar program as it prepares for a key meeting with the FDA.
Read more →AEONAEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data
AEON Biopharma has reported promising results for its biosimilar product ABP-450, demonstrating an identical amino acid sequence to BOTOX along with highly similar functional analysis data. These findings support AEON's aim for accelerated U.S. market entry, as they prepare for an important FDA meeting on November 19, 2025, to discuss the next steps in the biosimilar development process. The company is optimistic that their product will contribute significantly to the U.S. therapeutic neurotoxin market, which is valued at over $3 billion.
Read more →AEONAEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
AEON Biopharma has announced a meeting with the FDA on November 19, 2025, to discuss the analytical development plan for its biosimilar product ABP-450. This meeting is significant as it represents an alignment step with the FDA regarding the key quality attributes and initial data of the product. ABP-450 is being developed as a biosimilar to BOTOX, and AEON aims to advance its market entry in the U.S. therapeutic neurotoxin sector, which is valued at over $3 billion annually. The outcomes of the meeting will be reported by AEON after its conclusion.
Read more →AEONAccelerated Access to the $3B+ U.S. Neurotoxin Therapeutic Market via Biosimilarity CORPORATE PRESENTATION SEPTEMBER 2025 NYSEAMERICAN: AEON © 2 0 2 5 A E O N B I O P H A R M A This presentation includes forward-loo
AEON Pharmaceuticals presented a corporate update on ABP-450, their investigational biosimilar targeting the neurotoxin therapeutic market. The company highlights ABP-450's potential benefits, including cost reduction for patients and clinicians, aiming to capture a share of the projected $3 billion U.S. market. The product has received FDA approval for aesthetics and is positioned for broader therapeutic applications. Furthermore, the company anticipates a favorable response from payers and hopes to improve patient access through its biosimilar strategy.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30
AEON Biopharma has reported its financial results for the second quarter of 2025 and outlined key upcoming milestones. The company is on track with its development of ABP-450, a proposed biosimilar to Botox, and expects to complete critical analyses by the third quarter of 2025. A Type 2a meeting with the FDA is anticipated in the fourth quarter, aimed at aligning on development steps. Despite strong progress, uncertainty about the completion of studies and regulatory outcomes remains.
Read more →AEONAEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
AEON Biopharma has reported its financial results for Q2 2025, highlighting significant progress toward its biosimilar development of ABP-450, a botulinum toxin product aimed at gaining entry into the U.S. market. Key milestones include the anticipated completion of primary structure analysis and select functional studies by Q3 2025, with a Type 2a meeting with the FDA expected in Q4 2025. The company believes this meeting could provide insights into their development trajectory and potential for enhancing patient accessibility to therapeutic neurotoxins.
Read more →AEONCorporate Presentation - Aegis Capital Healthcare Conference May 2025 PrabotulinumtoxinA Redefining access to therapeutic botulinum toxins 2 Forward-Looking Statements This presentation includes forward-looking statement
AEON Biopharma presented at the Aegis Capital Healthcare Conference, detailing its strategy for ABP-450, a biosimilar to Botox. The company aims to leverage FDA guidance for broad label access and hopes to finalize FDA meetings targeting 2025 to review study results. AEON believes that its therapeutic-only BLA can circumvent pricing issues in the aesthetic market, creating potential for significant market share in various therapeutic indications. Upcoming catalysts, including completion of clinical studies and regulatory evaluations, are expected to advance their biosimilar pathway.
Read more →AEONAEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
AEON Biopharma will present at the Aegis Capital Corp. Virtual Conference on May 21, 2025. The presentation will be led by Rob Bancroft, the company's President and CEO. AEON is developing ABP-450, a botulinum toxin complex for therapeutic uses, which has already been approved for cosmetic applications in other markets.
Read more →AEONAEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
AEON Biopharma has reported its first quarter 2025 financial results, highlighting progress in its biosimilar development program for ABP-450. The company is pursuing a 351(k) regulatory pathway to potentially bring ABP-450 to the U.S. market under a single approval. Newly appointed CEO Rob Bancroft expressed optimism about enhancing patient access and cost-efficiency in the therapeutic toxin market.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except share and per share data) Three Months Ended
AEON Biopharma, Inc. has reported its financial results for the first quarter of 2025 and provided an update on its development plans. The company is pursuing a biosimilar regulatory pathway for ABP-450, which aims to utilize BOTOX as a reference product. Recent leadership changes have seen Rob Bancroft appointed as the new CEO, who is optimistic about expanding their product offerings. However, the company also faces significant financial losses and risks associated with regulatory processes.
Read more →AEONAEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
AEON Biopharma has announced that the NYSE American has accepted its plan to regain compliance with listing standards. The company has until August 3, 2026, to meet these standards, during which it will be subject to periodic reviews. AEON is focused on developing its botulinum toxin complex for therapeutic indications.
Read more →AEONAEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
AEON Biopharma has appointed Rob Bancroft as its new President and CEO, effective April 29, 2025. Bancroft brings over 25 years of experience in the life sciences sector, particularly in therapeutic toxins. He aims to advance AEON's ABP-450 program, which seeks to offer a biosimilar alternative to BOTOX, enhancing patient access and affordability.
Read more →AEON▼ -7.3%on this news
AEON Biopharma Announces CEO Transition
AEON Biopharma announced a leadership transition as Marc Forth steps down as CEO to pursue another opportunity, effective April 4, 2025. Jost Fischer, the current Chairman, will serve as interim CEO while the Board searches for a permanent replacement. The company continues to advance its ABP-450 biosimilar program, with a meeting with the FDA anticipated in late 2025.
Read more →AEON▼ -8.6%on this newsshared move
Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON's future financial or o
AEON Biopharma has announced the resignation of Marc Forth as President and CEO, effective April 4, 2025, to pursue another opportunity. Jost Fischer, currently the Chairman, will serve as Interim CEO while the Board searches for a permanent replacement. Despite the leadership change, AEON is making strides in its regulatory process for the ABP-450 botulinum toxin complex and anticipates progress in meetings with the FDA in the second half of 2025. The company remains confident in its strategic direction and the expertise of its management team.
Read more →AEON▲ +8%on this newsshared move
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
AEON Biopharma announced its financial results for Q4 and full year 2024, highlighting its efforts in biosimilar development for ABP-450. The company has initiated analytical studies and plans to meet with the FDA in 2025 under the 351(k) regulatory pathway, which could allow for broader market access. Additionally, AEON secured $20 million in financing to support its operations and development programs, aiming to increase shareholder value.
Read more →AEON▲ +8%on this newsshared move
closing of the Merger. The accompanying financial statements include Successor periods for the three months ended
AEON Biopharma has reported its fourth quarter and full year financial results for 2024, highlighting progress in its biosimilar development program for ABP-450. The company is pursuing a 351(k) regulatory pathway, with plans to meet the FDA for a BPD Type 2a discussion in the latter half of 2025. Additionally, AEON secured $20 million in funding through a public offering, which is expected to support its operational plans through 2025. Despite some financial challenges indicated by its accumulated deficit, the company remains optimistic about its future prospects.
Read more →AEON▲ +39.4%on this news
Corporate Presentation March 2025 PrabotulinumtoxinA Potential biosimilar for therapeutic indications 2 Forward-Looking Statements This presentation includes forward-looking statements. All statements other than statemen
AEON Biopharma is advancing its PrabotulinumtoxinA as a potential biosimilar to Botox, aiming for approval across 12 therapeutic indications. The company anticipates significant sales growth, projecting over $2.7 billion in US therapeutic revenue for 2024. The biosimilar pathway is expected to facilitate faster market entry while leveraging existing data for approval, addressing a growing patient population with limited competition in the therapeutic botulinum toxin market. AEON aligns with FDA for its comparative analytical studies to support this initiative.
Read more →AEON▼ -21.3%on this news
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
AEON Biopharma, Inc. will present a corporate overview at the Leerink Global Healthcare Conference from March 10-12, 2025, in Miami, FL. The company focuses on developing ABP-450, a botulinum toxin complex, for medical conditions, leveraging its experience in biopharmaceutical development. ABP-450 is already marketed for cosmetic use under the name Jeuveau.
Read more →AEON▼ -34.9%on this news· ran to -90% by day 3
AEON Biopharma, Inc. Announces Reverse Stock Split
AEON Biopharma, Inc. has announced a 1-for-72 reverse stock split to enhance its stock price and comply with NYSE American requirements. This decision was approved by stockholders during a Special Meeting held on February 24, 2025. The reverse split will take effect on February 26, 2025, allowing trading to resume under the existing ticker symbol.
Read more →AEON▼ -43.9%on this news· ran to -91% by day 3shared move
assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflecte
AEON Biopharma, Inc. has announced a 1-for-72 reverse stock split to comply with NYSE American requirements, effective February 26, 2025. This decision was ratified during a special meeting of stockholders held on February 24, 2025, aimed at increasing the stock's market price. Following the split, stockholder ownership percentages will remain unchanged, while fractional shares will be rounded up. The move is significant for the company as it continues to develop its botulinum toxin complex ABP-450.
Read more →AEON▼ -6.9%on this news
built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com . Forwar
AEON Biopharma has received a notice from NYSE American indicating non-compliance with listing standards due to a reported stockholders' deficit. The company reported losses in two of the last three fiscal years, necessitating a plan to regain compliance by March 5, 2025. If the plan is either not submitted or rejected, AEON may face delisting proceedings. Despite this setback, AEON continues to trade on the NYSE American and is committed to addressing the compliance issues.
Read more →AEON▼ -6.9%on this news
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
AEON Biopharma, Inc. has received a notice from NYSE American indicating non-compliance with listing standards due to a reported stockholders' deficit of $32.1 million and prior losses in two of the last three fiscal years. The company is required to submit a plan outlining actions to regain compliance by March 5, 2025. If the plan is accepted, AEON will be subject to ongoing monitoring. The notice does not affect the trading of AEON's shares, which will continue to be listed under the symbol 'AEON' with a 'below compliance' designation.
Read more →AEON▲ +5.2%on this news· ran to -33% by day 3
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
AEON Biopharma, Inc. has closed its previously announced $20 million underwritten public offering, consisting of 40 million Common Units. Each unit includes shares of stock along with Series A and Series B Warrants, both priced at $0.625 per share. Aegis Capital Corp., acting as the sole manager of the offering, exercised an over-allotment option for additional warrants. The proceeds from this transaction will be utilized for general corporate purposes and working capital.
Read more →AEON▼ -63.1%on this newsshared move
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
AEON Biopharma, Inc. has announced a public offering priced at approximately $20 million to support its clinical development efforts. The offering consists of 40 million common units, including shares and warrants, with proceeds expected to ensure financial stability through 2025. The funds will facilitate the necessary studies under the 351(k) regulatory pathway for their botulinum toxin complex, ABP-450. The transaction is anticipated to close on January 7, 2025, subject to standard conditions.
Read more →AEON▼ -63.1%on this newsshared move
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
AEON Biopharma, Inc. has announced a public offering to sell units consisting of shares of Common Stock and warrants. The offering is aimed at raising capital for general corporate and working capital needs, but it is subject to market conditions. AEON's product, ABP-450, is already approved in several international markets and is produced in a compliant facility. However, the company faces risks related to its financing and potential legal challenges.
Read more →AEON▼ -8.1%on this news· ran to -21% by day 3
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AEON Biopharma reported its financial results for Q3 2024 and provided updates on its biosimilar development program for ABP-450. The company held an advisory meeting with the FDA and is aligned on the regulatory pathway moving forward. Plans to initiate comparative studies are set for Q4 2024, pending resources. Despite progress, AEON faces challenges with capital resources, which may affect the execution of its strategy.
Read more →AEON▼ -8.1%on this news· ran to -21% by day 3
Unless the context otherwise requires, the "Company," for periods prior to the close of the Merger, refers to Old AEON, currently AEON Biopharma Sub, Inc. ("Predecessor"), and for the periods after the clos
AEON Biopharma has announced its third quarter 2024 financial results and provided a corporate update, highlighting progress in the development of biosimilar ABP-450. The company held a meeting with the FDA to align on the 351(k) regulatory pathway for approval, and plans to initiate necessary comparative analytical studies in Q4 2024. However, AEON is currently experiencing limitations in capital resources, which could impact its ability to execute its regulatory strategy moving forward.
Read more →AEON▲ +24%on this news
Corporate Presentation October 2024 PrabotulinumtoxinA Potential biosimilar for therapeutic indications 2 Forward-Looking Statements This presentation includes forward-looking statements. All statements other than statem
AEON's recent corporate presentation highlighted promising Phase 2 trial results for PrabotulinumtoxinA, showcasing significant improvements in treating cervical dystonia with comparable safety to existing botulinum products. No treatment-related discontinuations were reported, and the drug exhibits a favorable profile regarding adverse events. The upcoming steps include comparative analytical studies and a planned FDA meeting in 2025 to discuss the remaining study package. If successful, PrabotulinumtoxinA could position itself strongly in the biosimilar market for therapeutic applications.
Read more →AEON▲ +13.2%on this news
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
AEON Biopharma has announced a positive outcome from its recent advisory meeting with the FDA regarding the biosimilar ABP-450 (prabotulinumtoxinA). The company is aligned with the FDA on the requirements needed to move forward with the 351(k) regulatory pathway. Comparative analytical studies are planned to commence in Q4 2024, with a follow-up meeting scheduled with the FDA in 2025 to review these results. This positive alignment increases the likelihood of bringing the biosimilar product to the U.S. market, targeting both current and future indications of BOTOX.
Read more →AEONAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
AEON Biopharma, a clinical-stage biopharmaceutical firm, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. Marc Forth, the company's President and CEO, will provide a corporate overview at the event. Interested institutional investors may arrange one-on-one meetings with company representatives. AEON is advancing its botulinum toxin complex, ABP-450, which is already approved for cosmetic use and has therapeutic potential.
Read more →AEONAEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
AEON Biopharma has reported its financial results for the second quarter of 2024 and provided an update on its corporate initiatives. The company is advancing development of its investigational biosimilar, ABP-450, which aims to position itself as a competitive alternative to BOTOX. AEON plans to hold an initial advisory meeting with the FDA in the third quarter of 2024 and is preparing for a pivotal clinical study to compare ABP-450 to BOTOX in cervical dystonia treatment. The successful completion of this study could pave the way for regulatory approval under the 351(k) pathway.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30
AEON Biopharma, Inc. reported its financial results for the second quarter of 2024, highlighting advancements in its development plans for ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX. The company announced an upcoming advisory meeting with the FDA in Q3 2024 as part of its regulatory strategy. AEON also aims to initiate a pivotal clinical study comparing ABP-450 to BOTOX in treating cervical dystonia, pending funding. Despite these developments, AEON's financial statements reveal significant liabilities and an accumulated deficit.
Read more →AEON▼ -9.5%on this news
Corporate Presentation August 2024 PrabotulinumtoxinA Potential biosimilar for therapeutic indications 2 Forward-Looking Statements This presentation includes forward-looking statements. All statements other than stateme
AEON is advancing PrabotulinumtoxinA, a potential biosimilar to BOTOX, which has shown promising results in Phase 2 trials targeting cervical dystonia. With favorable regulatory conditions and anticipated FDA discussions in Q3 2024, the company aims to initiate a Phase 3 trial in 2025. Importantly, PrabotulinumtoxinA might establish a separate BLA focused solely on therapeutic indications, which could enhance reimbursement structures over traditional botulinum toxin products. Overall, the development and approval process is still ongoing as AEON navigates the regulatory landscape.
Read more →AEON▲ +7.8%on this news· ran to +37% by day 3
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
AEON Biopharma has announced a strategic reprioritization to develop ABP-450 as a biosimilar to BOTOX®, planning a pivotal Phase 3 study in cervical dystonia. This study will assess the non-inferiority of ABP-450 compared to BOTOX® under the 351(k) regulatory pathway, following an in-person FDA meeting scheduled for Q3 2024. Positive results could lead to a Biologics License Application, enabling the approval of ABP-450 for multiple therapeutic indications. AEON's shift to this pathway reflects its intent to capitalize on potential market opportunities in the U.S.
Read more →AEON▲ +8.7%on this news· ran to +19% by day 3
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
AEON Biopharma announced a strategic reprioritization and cost reduction plan, intending to extend its cash runway until Q4 2024. As part of this plan, the company has reduced its workforce by about 55% and discontinued the Phase 2 study of ABP-450 for chronic migraine after it failed to meet endpoints. AEON's leadership change includes the termination of its CFO and the appointment of new financial officers, indicating a shift in management as they seek additional capital for future developments. The company continues to analyze data from its discontinued studies while focusing on preserving resources.
Read more →AEONAEON Biopharma Reports First Quarter 2024 Financial Results
AEON Biopharma has announced its financial results for Q1 2024, revealing challenges with its ABP-450 product. The Phase 2 study for chronic migraine did not meet its primary or secondary endpoints, prompting further analysis. Conversely, the company noted a productive end-of-Phase 2 meeting with the FDA regarding its episodic migraine study. While the firm continues to pursue development across its pipeline, it faces significant financial challenges and a growing stockholder deficit.
Read more →AEONAEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) Three Months Ended
AEON Biopharma, Inc. reported its financial results for Q1 2024, highlighting its ongoing Phase 2 study of ABP-450 for chronic migraine, which failed to meet primary or secondary endpoints. Despite setbacks, the company had a constructive dialogue with the FDA regarding its episodic migraine study, where secondary endpoints were met, though not the primary one. The company also completed a $15 million private placement to support its operations. However, AEON's financial standing reflects a growing deficit and significant operating losses.
Read more →AEON▼ -6.2%on this newsshared move
AEON Biopharma Provides Update on Development Pipeline
AEON Biopharma has provided an update on its clinical development pipeline, highlighting the progress of ABP-450 for multiple medical indications. While the company noted disappointment with chronic migraine results, where the treatment did not surpass placebo, it remains optimistic about other indications, especially episodic migraine, where favorable secondary outcomes were observed. Notably, the upcoming Phase 3 study for cervical dystonia is ready to initiate, based on successful Phase 2 results. AEON is also advancing plans for studies in gastroparesis and PTSD.
Read more →AEONAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma announced preliminary results from an interim analysis of its Phase 2 trial for ABP-450, showing that the treatment for chronic migraine did not meet its primary endpoint. The active treatment arms displayed reductions in migraine days, but these did not achieve statistical significance compared to the placebo. The company plans to conduct further analyses to understand the unexpected placebo effect and is implementing cash preservation measures while reviewing strategic options for the drug's development.
Read more →AEONAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine - Trial did not meet primary endpoint
AEON Biopharma announced that its Phase 2 trial of ABP-450 for chronic migraine prevention did not meet its primary endpoint. The interim analysis, involving 325 patients, indicated that the reductions in migraine days for both active arms were not statistically significant compared to the placebo group. Following these results, AEON is re-evaluating its development strategy for ABP-450 and has initiated measures for cash preservation. The company expressed disappointment but acknowledged the utility of the data gathered during the trial.
Read more →AEONAbout AEON Biopharma AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating me
AEON Biopharma announced the redemption of all outstanding public warrants to purchase shares of its Class A common stock. The redemption will occur for a price of $0.10 per warrant if certain conditions are met, specifically regarding the last sales price of the Common Stock. Additionally, after the notice of redemption, warrant holders can only exercise their warrants on a cashless basis. AEON continues to focus on its proprietary botulinum toxin complex, ABP-450, which is being developed for various medical conditions.
Read more →AEONPredecessor periods has been placed in the consolidated financial statements and in the tables to the notes to the consolidated financial statements to highlight the lack of comparability between these two
AEON Biopharma has reported its fourth quarter and full year 2023 financial results, highlighting key milestones achieved in its migraine treatment programs. A productive end-of-Phase 2 meeting with the FDA has paved the way for pivotal Phase 3 trials aimed at preventing episodic and chronic migraine. Topline data from an interim analysis of the ongoing Phase 2 study is anticipated for Q2 2024, with full study results expected in Q3 2024. Additionally, AEON has secured $15 million in funding through private placement agreements.
Read more →AEONAEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma has announced the redemption of all outstanding Public Warrants for its Class A common stock, effective March 29, 2024. The redemption price is set at $0.10 per warrant, and the public warrants must now be exercised on a cashless basis. This move comes as AEON has recently completed a Phase 2 study for its product ABP-450 and is focused on development for chronic migraine and cervical dystonia with an exclusive rights portfolio. The company emphasizes its commitment to regulatory compliance in its manufacturing processes.
Read more →AEONAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AEON Biopharma has reported its financial results for Q4 and full year 2023, announcing a positive end-of-Phase 2 meeting with the FDA regarding its migraine treatment programs. The company is set to release topline data from an interim analysis of its ongoing Phase 2 chronic migraine study in Q2 2024, with full results expected in Q3 2024. Additionally, AEON has secured $15 million through private placement agreements to enhance its late-stage clinical development initiatives.
Read more →AEONAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AEON Biopharma has announced a successful end-of-Phase 2 meeting with the FDA regarding its product ABP-450 for migraine prevention. Both entities are aligned on the study design and primary endpoints for future Phase 3 trials. An interim analysis from the ongoing Phase 2 trial, which includes 492 patients, is anticipated to yield results in Q2 2024. Top-line data for the complete cohort is still on track for release in Q3 2024.
Read more →AEONnegatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ mater
AEON Biopharma has announced a significant clinical update regarding its product ABP-450 for migraine prevention, following a productive meeting with the FDA. The company confirmed alignment on the trial design and endpoints for upcoming Phase 3 studies. Additionally, an interim analysis of the ongoing Phase 2 study will be conducted, with results expected in Q2 2024. AEON's efforts in developing ABP-450 reflect significant advances in addressing chronic migraine treatment.
Read more →AEONAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AEON Biopharma announced it has completed a $15 million financing transaction through the issuance of senior secured convertible notes with Daewoong Pharmaceutical. The funding is intended to support the late-stage clinical development of ABP-450 and general working capital. Concurrently, AEON terminated its forward purchase agreements, which the company believes will simplify its capitalization structure. The company anticipates appointing a member of Daewoong's senior management to its Board of Directors after the funding is complete. This financing follows a successful FDA meeting regarding the progression of ABP-450 into Phase 3 trials for episodic migraine treatment.
Read more →AEONAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AEON Biopharma has reported positive clinical and preclinical findings for its botulinum toxin complex, ABP-450, at the TOXINS 2024 conference. The Phase 2 data indicates that ABP-450 shows significant efficacy in treating cervical dystonia, achieving peak effects early within four weeks, with sustained benefits observed for up to 16 weeks. Furthermore, early-phase research demonstrated successful implementation of a novel Stellate Ganglion Block technique in preclinical models for PTSD treatment. AEON aims to advance ABP-450 into a proposed Phase 3 study following discussions with the FDA regarding the results obtained to date.
Read more →AEONAEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
AEON Biopharma has announced the completion of patient enrollment in its Phase 2 study of ABP-450 for chronic migraine prevention. The study has enrolled 492 patients across multiple sites in the U.S., Canada, and Australia. Topline data is anticipated to be released in Q3 2024, with plans for an FDA meeting in early 2024 to discuss the next steps for a Phase 3 program targeting episodic migraine. The company aims to modify the study design to enhance statistical power and address placebo response issues observed in previous studies.
Read more →AEONAEON Biopharma Reports Third Quarter 2023 Financial Results
AEON Biopharma announced its third quarter 2023 financial results, highlighting positive topline results from a Phase 2 trial of ABP-450 for episodic migraine, which supports progression to a pivotal Phase 3 study. The ongoing Phase 2 trial for chronic migraine is expected to complete enrollment by the end of 2023, with topline data anticipated in the second half of 2024. The company has successfully finalized its business combination and associated equity financing, bolstering its financial position for upcoming clinical trials. Recent data presentations showcased favorable outcomes for cervical dystonia, further demonstrating the potential of ABP-450 in treating neurological conditions.
Read more →AEONPRESS RELEASE On
AEON Biopharma reported its third-quarter 2023 financial results, highlighting positive topline results from a Phase 2 trial of ABP-450 for preventive migraine treatment. The company is advancing this program into a pivotal Phase 3 study and has successfully enrolled over 430 subjects in an ongoing chronic migraine trial, expected to complete by Q4 2023. AEON has also completed a business combination transaction, positioning itself to finance ongoing and future clinical trials.
Read more →AEONAEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AEON Biopharma announced topline results from its Phase 2 trial of ABP-450 for the preventive treatment of episodic migraine. While the primary endpoint of reducing monthly migraine days did not reach statistical significance against placebo, secondary endpoints showed positive responder rates. ABP-450 was found to be well-tolerated with a favorable safety profile, prompting plans to advance to a Phase 3 trial expected in the latter half of 2024. The company also continues its Phase 2 study for chronic migraine treatment, with topline results anticipated in 2024.
Read more →AEONAEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine - ABP-450 doses of 150 units and 195 units showed treatment effe
AEON Biopharma announced topline results from its Phase 2 trial of ABP-450 for episodic migraine prevention. The trial revealed a treatment effect of 4.8 and 5.0 days reduced in monthly migraine days for two dosing groups, despite not reaching statistical significance. Secondary endpoints showed significant improvement, especially in the ≥50% and ≥75% responder rates. The results support further development into Phase 3, expected to commence in the second half of 2024.
Read more →AEONAEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress
AEON Biopharma announced positive results from its Phase 2 clinical trial of ABP-450 for cervical dystonia during the IP-MDS congress. The study showed significant improvements in the Toronto Western Spasmodic Torticollis rating scale across various dosages. ABP-450 was found to be generally safe and well tolerated, with sustained benefits lasting at least 20 weeks. The company is now discussing a Phase 3 study with the FDA, which is expected to begin in 2024.
Read more →AEONAEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
AEON Biopharma has received a notice of allowance from the USPTO for its patent covering the use of botulinum toxins in treating migraine headaches. This patent, which pertains to the company's lead asset ABP-450, will offer protection in the U.S. until 2041. The patent supports AEON's strategy to use botulinum toxins for therapeutic indications and aligns with ongoing clinical studies for migraine treatment.
Read more →AEONINDEX TO FINANCIAL STATEMENTS TABLE OF CONTENTS ​ AEON BIOPHARMA, INC. ​ Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheets as of
AEON Biopharma, Inc. has released its financial statements for the years ended December 31, 2022 and 2021. The report outlines significant recurring losses, net capital deficiencies, and negative cash flows from operations. These financial troubles have raised concerns about the company's ability to continue operations as a going concern, highlighting its precarious financial position. The report also notes the absence of adjustments in the financial statements that might arise from this uncertainty.
Read more →AEONAEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
AEON Biopharma has announced the successful closing of its business combination with Priveterra Acquisition Corp., now listing under the symbols AEON and AEON WS on the New York Stock Exchange American. The company secured $50 million in financing as part of a larger $125 million capital arrangement to fund its operations, particularly towards its clinical development of ABP-450, a botulinum toxin complex. AEON anticipates topline data from its Phase 2 study for the preventive treatment of episodic migraine later this fall, alongside milestones for other clinical programs over the next 18 months. The company is also advancing studies for additional indications, including gastroparesis.
Read more →AEONCorporate Presentation July 2023 2 Forward Looking Statements This presentation includes forward - looking statements . All statements other than statements of historical facts contained in this presentation, including s
AEON's July 2023 corporate presentation discusses forward-looking statements concerning future actions and results. It highlights the potential of its product, ABP-450, particularly in the episodic migraine market, which could nearly triple its patient population. However, the company faces risks including legal proceedings after business combinations, the need to meet stock exchange standards, and competition in the therapeutic sector. Additionally, ongoing uncertainties may affect the accuracy of its projections.
Read more →AEONPriveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
Priveterra Acquisition Corp. announced that it has received authorization for its common stock and warrants to be listed on NYSE following its merger with AEON Biopharma. This business combination, which will result in Priveterra changing its name to AEON Biopharma, is expected to commence trading under the new ticker symbol 'AEON' on July 24, 2023. As of now, a significant number of Priveterra's shareholders have redeemed their shares, while the merger progresses towards completion with customary closing conditions pending.
Read more →AEONPriveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
Priveterra Acquisition Corp. has announced its intention to list on the NYSE following its business combination with AEON Biopharma, Inc. Upon finalizing this merger, AEON will become a wholly owned subsidiary of Priveterra, which will also change its name to AEON Biopharma, Inc. The transition to NYSE is anticipated to commence on July 24, 2023, with the new ticker symbol being "AEON." Until the transfer is completed, existing shares will continue trading on Nasdaq under the "PMGM" symbols.
Read more →AEONAEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
AEON Biopharma has announced arrangements for up to $125 million in financing in conjunction with its proposed business combination with Priveterra Acquisition Corp. This funding is comprised of committed financing from existing investors and potential financing through forward purchase agreements. The capital will support AEON beyond the anticipated release of Phase 2 study data for its investigational drug ABP-450. The business combination is expected to close in July 2023, pending stockholder approval and other conditions.
Read more →AEONAEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination Financing represents minimum cash required to consummate the business c
AEON Biopharma has partnered with Priveterra Acquisition Corp. to secure up to $125 million in financing for their proposed business combination. This funding is designed to meet the minimum cash required for the merger and to support AEON's operations through upcoming clinical data announcements. The AIM for the merger approval is set for July 2023, contingent upon stockholder consent and certain customary closing conditions being satisfied. Successful completion could enhance AEON's financing structure and accelerate its development in therapeutic areas including migraines.
Read more →AEONEXECUTION VERSION PRIVETERRA SPONSOR, LLC 300 SE 2nd Street, Suite 600 Fort Lauderdale, Florida 33301
The article details a letter agreement between Priveterra Sponsor, LLC and ACM ASOF VIII Secondary-C LP dated June 29, 2023. It outlines terms related to a Subscription Agreement and a Forward Purchase Agreement involving AEON Biopharma, Inc. Key elements include conditions regarding the transfer of common shares and the issuance of additional shares based on specified price thresholds. The agreement emphasizes regulatory compliance and the definitions of shares involved.
Read more →AEONCorporate Presentation May 2023 2 Disclaimer About This Presentation This investor presentation ("Presentation") does not constitute (i) a solicitation of a proxy, consent or authorization with res pect to any securities
AEON Biopharma, Inc. has released a corporate presentation detailing the proposed business combination with Priveterra Acquisition Corp. The presentation contains forward-looking statements regarding future performance and financial targets, which involve various risks and uncertainties. It emphasizes that actual outcomes may differ from projections due to a range of business and regulatory factors. Additionally, the presentation includes preliminary financial information awaiting final review.
Read more →AEONKOL EVENT: Botulinum Toxin and Migraine Prevention
AEON Biopharma discussed its upcoming Business Combination with Priveterra in a KOL event focusing on Botulinum Toxin's potential for migraine prevention. The presentation contains forward-looking statements and highlights the anticipated growth in demand for the company's products. However, it also outlines various risks, including potential legal challenges and the necessity of obtaining shareholder approvals for the Business Combination. Investors are cautioned against placing undue reliance on the forward-looking statements provided.
Read more →AEONAEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
AEON Biopharma will host a key opinion leader webinar on February 24, 2023, focusing on migraine treatments using botulinum toxin. The virtual event will feature experts discussing the current treatment landscape and AEON's developments in this area. AEON is progressing in clinical trials for its proprietary botulinum toxin complex, specifically targeting chronic and episodic migraines, promising updates for healthcare professionals and potential patients.
Read more →AEONUS-DOCS\138831380.2 AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th Live event scheduled for Friday, February 24th at 11:00
AEON Biopharma is set to host a Key Opinion Leader webinar on February 24th, discussing past, present, and potential future treatments for migraine. The event is part of the company's ongoing focus on its proprietary botulinum toxin complex, ABP-450, which has completed a Phase 2 study targeting migraine disorders. AEON's business combination with Priveterra is also under review, raising both opportunities and risks concerning its future operations and market position. The management team emphasizes their expertise in biopharmaceutical and botulinum toxin development as they navigate these developments.
Read more →AEONAEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
AEON Biopharma has confirmed that its development strategy and timelines for ABP-450 will not be affected by a recent Korean court ruling favoring Medytox in a trade secret dispute with Daewoong Pharmaceutical. The company has settled all litigation with Medytox, ensuring that ABP-450's supply remains uninterrupted. AEON plans to continue its clinical development and commercialization of ABP-450, focusing on treatments for debilitating conditions. The company's licensing agreement with Daewoong also secures manufacturing rights for its botulinum toxin complex injection, set for therapeutic use in key markets.
Read more →AEONAEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
AEON Biopharma has announced an additional capital commitment of at least $20 million from its existing investors. This funding is part of the proposed business combination with Priveterra Acquisition Corp., intended to support the advancement of AEON's product candidate, ABP-450. The additional funds account for nearly half of the minimum cash requirement for the proposed transaction. AEON's management expressed confidence in the partnership with Priveterra and the technology's path to commercialization.
Read more →AEONAEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination
AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination IRVINE, Calif., December 27, 2022 - AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company developing a proprieta
Read more →AEONAEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
– Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 – IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”
Read more →AEONAEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022 – – Topline data from Phase 2 study of ABP-450 for episodic migraine expected in Q4 2023 – –Robert Palmisano of Priveterra to become chairman of the Board of Directors; combi
Read more →AEONAEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology - Positive topline data from Phase 2 study of ABP-450 for c
Read more →AEONAEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults – – All three dosing arms demonstrated a median duration of effect greater than or equal to 20 weeks, the last point
Read more →AEONAEON Biopharma Raises $30 Million from Insiders
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indica
Read more →AEONAEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia
NEWPORT BEACH, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeuti
Read more →AEONAEON Biopharma Announces the Appointment of Alex Wilson as General Counsel
NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announ
Read more →AEONAEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications
NEWPORT BEACH, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection, today announ
Read more →AEONPriveterra Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report Fort Lauderdale
Priveterra Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report Lauderdale - June 4, 2021 - Priveterra Acquisition Corp. (the "Company") today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC ("Nasdaq")
Read more →AEONAEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
NEWPORT BEACH, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection, today annou
Read more →AEONPriveterra Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing
Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing April 1, 2021 Lauderdale - March 25, 2020 - Priveterra Acquisition Corp. (Nasdaq: PMGMU) (the "Company") today announced that, commencing April 1, 2021, holders of the units sold in t
Read more →AEONAEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- NEWPORT BEACH, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clini
Read more →AEONPRIVETERRA
PRIVETERRA ACQUISITION CORP. Assets Cash $ 2,577,115 Prepaid expenses 671,200 Total current assets 3,248,315 Cash held in Trust Account 276,000,000 Total assets $ 279,248,315 Liabilities and Stockholders' Equity Accounts payable and accrued expenses $ 982,55
Read more →AEONPriveterra Acquisition Corp. Announces Pricing of Upsized $240 Million Initial Public Offering Fort Lauderdale, FL
Priveterra Acquisition Corp. Announces Pricing of Upsized $240 Million Initial Public Offering Fort Lauderdale, FL - February 8, 2021 - Priveterra Acquisition Corp. (the "Company") today announced the pricing of its initial public offering of 24,000,000 units at a price of $1
Read more →AEONAEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
-Critical milestone transitions AEON Biopharma to clinical-stage company- -Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021- -Investment expected to provide funding for clinical programs into 2021- NEWPORT BEACH, Calif., Sept. 02, 2020 (G
Read more →Competitive Position
How AEON ranks across every disease it competes inCompetitive Position is a premium feature
See how AEON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial